#### Risk factors for severe illness and death in COVID-19: a systematic review

#### and meta-analysis

- Abraham Degarege<sup>1\*</sup>; Zaeema Naveed<sup>1</sup>; Josiane Kabayundo<sup>1</sup>; David Brett-Major<sup>1</sup>
- <sup>1</sup> Department of Epidemiology, College of Public Health, University of Nebraska Medical
- Center, Omaha, Nebraska, USA.

#### **Corresponding Author**

- Abraham Degarege, MS, PhD
- Assistant Professor
- Department of Epidemiology, University of Nebraska Medical Center
- Email: abraham.mengist@unmc.edu Phone: (1) 402-552-6682

## 

## 20 Abstract

#### 21 **Objectives**

22 This systematic review and meta-analysis synthesized the evidence on the impact of

- 23 demographics and comorbidities with clinical outcomes of COVID-19, including severe
- 24 illness, admission to the intensive care unit (ICU), and death.

#### 25 Methods

26 The PRISMA guidelines were followed to conduct and report this meta-analysis. The

27 protocol is registered in PROSPERO International prospective register of systematic

reviews (ID=CRD42020184440). Two authors independently searched literature from

29 PubMed, Embase, Cochrane library and CINHAL on May 6, 2020; removed duplicates;

30 screened titles, abstracts and full text using criteria; and extracted data from eligible articles.

31 A random-effects model was used to estimate the summary odds ratio (OR). Variations

32 among studies were examined using Cochrane Q and  $I^2$ .

### 33 **Results**

Out of 4,275 articles obtained from the databases and screened, 71 studies that involved

216,843 patients were abstracted and then, where appropriate, analyzed by meta-analysis.

36 The COVID-19 related outcomes reported were death in 26 studies, severe illness in 41

37 studies, and admission to ICU in 11 studies. Death was significantly correlated with

hypertension (OR 2.60, 95% CI 1.95–3.25,  $I^2 = 52.6\%$ , n= 13 studies), cardiovascular disease

39 (5.16, 4.10–6.22, 0.0%, 6), diabetes (2.11, 1.35–2.87, 67.4%, 12), chronic respiratory disease

40 (2.83, 2.14–3.51, 0.0%, 9), cerebrovascular diseases (5.14, 1.08–9.19, 0.0%, 2), male sex

(1.34, 1.18 – 1.50, 38.7%, 16), age older than 60 (6.09, 3.53 – 8.66, 95.5%, 6) or 65 years

42	(3.56, 1.21 – 5.90, 18.2%, 6). Severe illness was also significantly associated with
43	hypertension (1.70, 1.30 –2.10, 47.8%, 21), cardiovascular diseases (2.04, 1.01–3.08, 30.6%,
44	10), diabetes (1.65, 1.23–2.08, 24.9%, 18), male sex (1.35, 1.23 – 1.47, 0.0%, 32) and age at
45	least 60 (4.91, 1.35 – 8.47, 0.0%, 4) or 65 (2.55, 1.94 – 3.17, 24.5%, 9) years. Among
46	hospitalized patients, the odds of admission to ICU was greater in individuals who had
47	cardiovascular diseases (1.36,1.04–1.69, 0.0%, 4), diabetes (1.55, 1.20–1.90, 0.0%, 5) and
48	chronic respiratory disease (1.52, 1.09–1.94, 0.0%, 5) than those who were not having these
49	comorbidities.
50	Conclusions
51	Older age and chronic diseases increase the risk of developing severe illness, admission to ICU
52	and death among COVID-19 patients. Special strategies are warranted to prevent SARS-CoV-2
53	infection and manage COVID-19 cases in those with vulnerabilities.
54	
55	Keywords: COVID-19, severe illness, death, demographics, comorbidities
56	
57	
58	
59	
60	
61	

62

# 63 Introduction

While the numbers of COVID-19 pandemic are a moving target, over 27 million have been 64 infected worldwide, with more than 881 thousand deaths as of September 7, 2020 [1]. Due 65 66 to potential differences in immunity and genetics, the clinical course of SARS-CoV-2 infection and related death is expected to vary with human health and demography status [2-67 4]. However, precise factors of importance and their relative roles are not well defined. 68 Study findings on population groups that are more susceptible to severe illness and risk 69 factors for the clinical outcomes in COVID-19 patients remain contradictory [5-9]. While 70 some studies reported an increased risk of developing severe illness and death in COVID-19 71 72 patients with hypertension [5-7], cardiovascular diseases [5,7], diabetes [5,6], chronic respiratory diseases [5,6], cancer [6], chronic kidney diseases [6], cerebrovascular disease 73 74 [6], smoking history [8], ages older than 60 years [7], and male gender [7], a limited number of studies reported lack of correlation between these comorbidities and disease 75 progression or clinical outcomes in COVID-19 patients [9, 10]. 76

Meta-analyses that examined predictors of severe illness and death in COVID-19 patients involved data generated mainly from China and were based on a small number of studies (<15) [11-13]. Although two meta-analyses summarized data based on China, Europe and the USA [14,15], one of these did not examine the effect of some important comorbidities such as cancer, chronic liver disease, and cerebrovascular disease on the risk of admission in ICU or other clinical outcomes [14], the other one searched articles available only in PubMed [15], and both at the time of this submission were not peer-reviewed and are preliminary in nature [14,15]. The

84	relevant literature important to incorporate in systematic review continues to grow, as our
85	collective experience with COVID-19 grows. A better understanding of both striking and
86	subtle variations in patients and their circumstances and their experience with SARS-CoV-2
87	infection would inform the continued development of improved interventions to reduce
88	morbidity and mortality from COVID-19. Therefore, following PRISMA guidelines, we
89	systematically summarized and assessed literature published before May 6, 2020, and where
90	appropriate to the data, conducted a meta-analysis of risk factors of severe illness,
91	admission to ICU, and death among COVID-19 patients.

## 92 Methods

## 93 **Protocol and registration**

94 A protocol developed following the Preferred Reporting Items for Systematic Reviews and

95 Meta-analyses (PRISMA) checklist guided the execution and reporting of this meta-analysis (S1

96 Table) [16]. The protocol is registered in PROSPERO International prospective register of

97 systematic reviews (ID=CRD42020184440)) [17].

## 98 Inclusion and Exclusion criteria

All retrospective, cross-sectional, and prospective clinical and epidemiological studies except
individual case studies (comprehensive inclusion case series allowed), which reported the
prevalence or odds of death, severe illness, or admission to ICU and stratified by comorbidities
or demographic status among COVID-19 patients were included in the meta-analysis.
Unpublished studies and non-peer-reviewed preprints in repositories, case studies with fewer
than 10 samples or reports, letters, conference abstracts, protocol, gray literature, review

105	protocols and articles, irrelevant studies (on different topics), and animal or in vitro studies were
106	excluded. However, these sources were used to find additional eligible studies.

#### **Outcome and exposure measures** 107

108	The primary	y outcome was death.	Secondary outcomes	were severe illness and	l admission to IC	ĽU.
-----	-------------	----------------------	--------------------	-------------------------	-------------------	-----

Severe illness was defined as having one of the following: SpO2 < 94%; respiratory rate >30109

breaths per minute; lung infiltrates in >50% of lung fields by either plain or computed 110

111 tomography radiography; arterial partial pressure of oxygen to fraction of inspired oxygen

112 (PaO2/FiO2) <300 mmHg; or, organ dysfunction. Organ dysfunction include respiratory failure

as evidenced by mechanical ventilation, myocardial injury as evidenced by the need for 113

catheterization or troponin elevation, renal injury as evidenced by the need for dialysis or a 50% 114

115 decrease in renal function as assessed by either creatinine rise or decline in glomerular filtration

rate, hepatic failure, pulmonary embolus, or stroke/ cerebrovascular accident [18]. 116

117 The exposure variables were demographic (age, gender, tobacco use) and comorbidities,

118 including hypertension, diabetes, cardiovascular disease, chronic respiratory disease, chronic

119 kidney disease, chronic liver disease, cerebrovascular disease, and cancer.

#### Search methods for identification of studies 120

121

122 An article search was conducted in parallel in PubMed, Embase, Cochrane Library, and

CINAHL. The search terms were (obesity OR hypertension OR Asthma or nutrition OR age OR 123

- gender OR ethnicity OR race OR income OR poverty OR pregnancy OR "Breastfeeding" OR 124
- 125 "medical conditions" OR medications OR "chronic diseases" OR influenza or stroke OR HIV
- OR cancer OR diabetes OR "cardiovascular disease" OR "coronary heart disease" OR "chronic 126

127 respiratory disease" OR "Sequential Organ Failure Assessment" OR smoking OR "co infection" 128 OR comorbidity OR comorbidities or risk) AND (clinical OR severe OR complications OR mortality OR DEATH) AND ("coronavirus disease 2019" OR "COVID-19" OR "Severe acute 129 130 respiratory syndrome coronavirus 2" OR SARS-CoV-2 OR "Coronavirus 2" OR "2019 novel coronavirus"). Additional details of the search are available in the supplementary files (S2 131 Table). After transferring articles searched from the four databases to RefWorks and removing 132 duplicates, the titles and abstracts were screened based on the inclusion and exclusion criteria. 133 Articles approved for full-text review were further screened based on eligibility criteria. The 134 135 article search and screening processes were conducted by two authors independently. The two authors resolved differences by discussion. A third author was available to mediate disagreement 136 following an independent review. 137

### 138 **Data collection**

139 Data on author, study area/country, study design, sample size, crude or adjusted odds ratio (OR) of death, severe illness or admission to ICU along with 95% confidence interval (CI) among 140 COVID-19 patients with comorbidities vs without comorbidities or different demographic status 141 were abstracted from each study. In addition, when OR was not reported, raw data was used to 142 estimate the crude ORs of death, having severe illness or admission to ICU among COVID -19 143 patients with comorbidities vs without comorbidities or different demographic status per study. 144 Two authors abstracted and entered data into the excel sheet independently and compared their 145 results. The final data used for analysis was approved by the two authors upon discussion. 146

## 148 **Quality and risk of bias**

149 The risk of bias and quality of the studies included in this review was evaluated using the Effective Public Health Practice Project tool [19]. The Effective Public Health Practice Project 150 151 tool uses six criteria: selection bias, design, confounders, blinding, data collection, and 152 withdrawal/dropout, to examine the studies' quality. Each study's quality was determined as low, 153 moderate, and high for each of the six criteria using two items for each criterion. The study's 154 overall quality was determined as high when the study has no weak rating for each of the six 155 characteristics and moderate when the study has one weak rating in one of the six characteristics. 156 The studies were grouped as low quality when the ratings for two or more characteristics were 157 low.

#### 158 **Data analysis**

159 Percent residual variation among studies due to heterogeneity was estimated using Moran's I-160 squared [20]. Statistical significance of the heterogeneity was tested using the Cochran's Q chi-161 square test [20]. The odds ratios of the studies combined in the meta-analysis to estimate the 162 summary OR were both adjusted and unadjusted estimates. A random-effect model using the Der 163 Simonian and Laird method was used to estimate the summary ORs. When heterogeneity was high ( $I^2$ >60%), subgroup analysis was performed to estimate the summary ORs after grouping 164 165 studies by study area/country and study design. Meta-regression was used to explore the sources 166 of heterogeneity at study-level covariates by examining the linear relationship between ORs and 167 study area/country, study design and sample size [21]. A funnel plot that displays the odds ratio 168 estimate against their standard errors was used to evaluate publication bias among the studies included in the meta-analyses [22]. Statistical significance of the asymmetry of the funnel plot 169

was tested using the Egger's regression test (bias if p<0.1) [23]. A 95% CI and alpha of 0.05</li>
were used to assess the significance of OR.

# 172 **Results**

The initial search of articles from the databases using the keywords resulted in 4275 articles 173 174 (PubMed=1986, Embase= 2006, CINAHL =224, and Cochrane Library = 59) out of which 1527 175 were duplicates (Fig 1). Of the non-duplicate 2748 articles, 2444 were ineligible after screening 176 the titles and abstracts, and 233 articles were excluded after full-text review. This resulted in 71 177 articles appropriate for inclusion in the systematic review [5-10, 24-89], and 60 of them were also included in the meta-analysis. The majority of the studies were conducted in China 178 179 (n=53), and the others from South Korea (n=2), Iran (n=1), Europe (n=6) and USA (n=9) 180 (S1 Table 3). Study designs included retrospective (n=42), cross-sectional (n=25), and prospective (n=4). Clinical outcomes reported were death in 34 studies, severe illness in 45 181 182 studies, and admission to ICU in 11 studies. Exposure variables examined in the studies included hypertension, cardiovascular disease, diabetes, chronic respiratory disease, cancer, 183 chronic kidney disease, chronic liver disease, cerebrovascular disease, smoking, age and 184 185 sex.

Fig 1. PRISMA flow diagram. Number of articles retrieved from databases, screened, excluded,and included

## 188 Hypertension

189 Out of 71 studies approved for inclusion in this review, 38 examined the correlation of

190 hypertension with death, severe illness, and admission to ICU among COVID-19 patients. Out of

the 38 studies, 36 included in the meta-analyses. Figure 2 shows summary estimates of the odds

192 ratio of death (vs survival: n=13 studies), severe illness (vs moderate or mild: n=21 studies), and 193 admission to ICU (vs non-ICU: n=4 studies) among hypertensive vs non-hypertensive patients. 194 While some studies reported increased odds of death (n=9 studies) and severe illness (n=10195 studies) among hypertensive patients, others reported a lack of correlation between hypertension and death (n=4 studies) or severe illness (n=11 studies). A summary analysis of pooled data from 196 197 these studies showed moderate to high heterogeneity. Though, there were greater odds of death (OR 2.60, 95% CI 1.95–3.25,  $I^2 = 52.6\%$ , number of studies (n)= 13, number of participants 198 (N)=53,222 ) and severe illness (OR 1.70, 95% CI 1.30 -2.10,  $I^2 = 47.8\%$ , n=21, N=6.172) 199 among hypertensive as compared to non-hypertensive patients. The odds of admission to ICU 200 were comparable between those who were hypertensive vs those who were not hypertensive (OR 201 1.20, 95% CI 0.30 –2.18,  $I^2 = 79.2\%$ , n=5, N=1,832). 202

Fig 2. Forest plot showing the relationship of hypertension with the odds of death, severe illness and admission in ICU among COVID-19 patients.

## 205 Cardiovascular disease

Twenty studies examined the nature of the relationship of cardiovascular disease with the odds of

207 developing death (n=7), severe illness (n=11) and admission to ICU (n=5) among COVID-19

208 patients. Out of the twenty studies, the majority showed higher odds of death (n=6) and severe

209 illness (n=8) among COVID-19 patients with cardiovascular disease (Fig 3). The remaining 1 out

of 7 studies showed a lack of association between cardiovascular disease and death, and 3 out of

- 211 11 showed a lack of association between cardiovascular disease and the odds of developing
- severe illness among COVID-19 patients. A meta-analysis of the studies showed higher odds
- of death (OR 5.16, 95% CI 4.10–6.22,  $I^2 = 0.0\%$ , n=6, N=47,134), severe illness (OR 2.04, 95%

214 CI 1.01–3.08,  $I^2 = 30.6\%$ , n=11, N=48,535) and admission to ICU (OR 1.36, 95% CI 1.04–1.69,

 $I^2 = 0.0\%$ , n=5, N=8,346) among COVID-19 patients who had cardiovascular disease as

compared to those without this health problem (Fig 3).

Fig 3. Forest plot showing the relationship of cardiovascular disease with the odds of death,

severe illness and admission in ICU among COVID-19 patients.

## 219 **Diabetes**

Diabetes also is posited to be linked with the risk of developing severe illness and death among 220 COVID-19 patients. Twelve studies examined if having diabetes is correlated with the odds of 221 death among COVID-19 patients, half of which reported increased odds of death in COVID-19 222 patients with diabetes. Correlation of having diabetes with the odds of developing severe illness 223 224 and the odds of admission to ICU was assessed in 18 (eight reported increased odds) and five (two reported increased odds) studies, respectively. A summary analysis of these studies showed 225 greater odds of death (OR 2.11, 95% CI 1.35–2.87,  $I^2 = 67.4\%$ , n=12, N=59281), severe illness 226 (OR 1.65, 95% CI 1.23–2.08, I<sup>2</sup> = 24.9%, n=18, N=5811) and admission to ICU (OR 1.55, 95% 227 CI 1.20–1.90,  $I^2 = 0.0\%$ , n=5, N=8469) among patients with diabetes than those who had no 228 229 diabetes (Fig 4).

Fig 4. Forest plot showing the relationship of diabetes with the odds of death, severe illness andadmission in ICU among COVID-19 patients.

## 232 Chronic respiratory disease

Of 71 included studies, 19 compared the odds of death *vs* survival (n=9), severe *vs* moderate or

mild illness (n=9), and admission to ICU vs not (n=4) among COVID-19 patients who had

235 chronic respiratory disease vs those without this problem. Of the 9 studies which compared the 236 odds of death vs survival, six reported significantly greater odds of death among COVID-19 patients with chronic respiratory disease, but three documented lack of association between 237 238 chronic respiratory disease and the odds of death. On the other hand, out of the 9 studies which compared the odds of severe vs mild or moderate illness among COVID-19 patients, only three 239 reported significantly greater odds of severe illness, but five showed a lack of association 240 241 between chronic respiratory disease and the odds of developing severe illness. One study 242 reported lower odds of severe illness among COVID-19 patients with chronic respiratory disease as compared to those without chronic respiratory disease. Meta-analysis of the 19 studies showed 243 244 association of chronic respiratory disease with increased odds of death (OR 2.83, 95% CI 2.14– 3.51,  $I^2 = 0.0\%$ , n=9, N=59,624) and admission to ICU (OR 1.52, 95% CI 1.09–1.94,  $I^2 = 0.0\%$ , 245 246 n=5, N=8,346), but there was lack of correlation of the disease with severe illness (OR 1.39, 95%) CI 0.15–2.64,  $I^2 = 27.0\%$ , n=9, N=48,381) among COVID-19 patients (Fig 5). 247

Fig 5. Forest plot showing the relationship of chronic respiratory diseases with the odds of death,
severe illness and admission in ICU among COVID-19 patients.

### 250 Cancer

Thirteen studies examined the nature of the relationship of cancer with the odds of death (n=5), severe illness (n=6) and admission to ICU (n=3) among COVID-19 patients. Increased odds of death, severe illness and admission to ICU among COVID-19 patients who had cancer was reported in 2 (out of 5), 3 (out of 6) and 1 (out of 3) studies, respectively. The remaining studies showed a lack of association between having cancer and the odds of death (n=3), severe illness (n=3) and admission to ICU (n=2) among COVID-19 patients. Meta-analysis of the 13 studies

showed lack of association of cancer with the odds of death (OR 1.72, 95% CI 0.39 – 3.05,  $I^2 =$ 

258 0.0%, n=5, N=46,793), severe illness (OR 2.32, 95% CI 0.45 – 4.19,  $I^2 = 0.0\%$ , n=6, N=3,169)

and admission to ICU (OR 1.79, 95% CI -0.74 – 4.31,  $I^2 = 77.1\%$ , n=3, N=1,804) among

260 COVID-19 patients (S1 Fig).

## 261 Chronic kidney disease

Twelve studies examined the nature of the relationship of chronic kidney disease with the odds 262 of death (n=3), severe illness (n=7) and admission to ICU (n=2) among COVID-19 patients. Of 263 the 12 studies, two showed increased odds of death (n=1) or severe illness (n=1) among COVID-264 19 patients who had vs didn't have chronic kidney disease. The remaining 10 studies showed a 265 lack of association of chronic kidney disease with the odds of death (n=3), severe illness (n=3)266 267 and admission to ICU (n=2). Meta-analysis of the 12 studies showed lack of association of chronic kidney disease with the odds of death (OR 2.32, 95% CI 0.06 - 4.58,  $I^2 = 0.0\%$ , n=3, 268 N=4951), severe illness (OR 1.42, 95% CI 0.46 -2.38,  $I^2 = 0.0\%$ , n=7, N=7788) and admission 269 to ICU (OR 1.37, 95% CI 0.88–1.86,  $I^2 = 0.0\%$ , n=2, N=6653) among COVID-19 patients (S2 270 Fig). 271

## 272 Chronic liver disease

Out of the 71 studies included in this review, only seven tested the association of chronic liver disease with death or severe illness in COVID-19 patients. Of the seven studies, the only one reported a correlation of chronic liver disease with COVID-19 severity. A summary analysis of the seven studies showed lack of correlation of chronic liver disease with death (OR 1.41, 95% CI -2.20 – 5.02,  $I^2 = 0.0\%$ , n=2, N=352), severe illness (OR 1.35, 95% CI 0.67–2.03,  $I^2 = 0.0\%$ , n=4, N=6855) and admission to ICU (OR 1.77 95% CI 0.65 – 4.80, n=1, N=6637) (S3 Fig).

## 279 Cerebrovascular diseases

Six studies reported findings on the odds of death (n=2), severe illness (n=2) and admission to ICU (n=2) among COVID-19 patients with cerebrovascular diseases *vs* those without having this comorbidity. Two studies by Guan et al. 2020 [6] and Wang et al. 2020 [72] reported increased odds of death among COVID-19 patients with cerebrovascular diseases. Another two studies also showed association of cerebrovascular diseases with increased odds of developing severe illness [37] and admission to ICU [8]. A meta-analysis of the two studies showed increased odds of death among COVID-19

patients with cerebrovascular diseases (OR 5.14, 95% CI 1.08 – 9.19,  $I^2 = 0.0\%$ , n=2, N=1,983), but the odds of severe illness (OR 2.18, 95% CI -0.07 – 4.44,  $I^2 = 0.0\%$ , n=2, N=928) and admission to ICU (OR 4.09, 95% CI -0.20 – 8.38,  $I^2 = 0.0\%$ , n=2, N=1,606) were similar between patients with cerebrovascular diseases and those without this comorbidity (S4 Fig).

## 291 Smoking

A total of 14 studies included in the current meta-analyses that examined the impact of tobacco 292 smoking on the clinical outcomes of COVID-19. Of these 14 studies, most showed a lack of 293 association of smoking with death (2 out of 2), severe illness (9 out of 11), or admission to ICU 294 (1 out of 1) among COVID-19 patients. Only two studies showed increased odds of severe 295 296 illness among COVID-19 patients who were former or current smokers than non-smokers. A meta-analysis of the studies showed similar odds of death (OR 0.90, 95% CI 0.70 – 1.10,  $I^2 =$ 297 0.0%, n=2, N=9155) or severe illness (OR 1.31, 95% CI 0.96 – 1.67, I<sup>2</sup>= 0.0%, n=11, N=4509) 298 299 among COVID-19 patients who were former or current smokers than non-smokers (S5 Fig).

300

### 301 Age

Out of the 71 studies, 27 examined the effect of age on the odds of death, severe illness and 302 303 admission to ICU. Out of 27 studies, 15 treated age as  $>65 vs \le 65$  years and 10 as  $\ge 60 vs < 60$ 304 years. Of the 15 studies which treated age as > 65  $vs \le 65$  years, 13 reported increased odds of death (n=5) or severe illness (n=9) among patients of ages > 65 years as compared to those of  $\leq$ 305 65 years. Similarly, nine studies that treated age as  $\geq 60 vs < 60$  years reported increased odds of 306 death (n=6) or severe illness (n=3) among patients of ages  $\geq 60$  years as compared to those < 60 307 308 years. Chen et al. [89] also showed an increased hazard ratio of severe illness among patients of 309 Age  $\geq$  65 years as compared to younger individuals (Hazard ratio 3.43; 95% CI, 1.24-9.5). Dong et al. [88] also reported an increased prevalence of severe COVID-19 illness in children than 310 311 those of adult patients. However, a study showed similar odds of severe illness among 312 individuals of ages  $\ge 60 vs < 60$  years [80]. Two studies also reported similar odds of admission to ICU among individuals of ages > 65 years vs those of  $\leq$  65 years [10,25]. A meta-analysis of 313 these studies showed a greater odds of death (OR 3.56, 95% CI 1.21 - 5.90,  $I^2 = 18.2\%$ , n=6, 314 N=13,964) and severe illness (OR 2.55, 95% CI 1.94 – 3.17,  $I^2 = 24.5\%$ , n=9, N=3374) among 315 316 patients of ages > 65 years than those of  $\leq$  65 years. The summary odds ratio estimates of death (OR 6.09, 95% CI 3.53 - 8.66,  $I^2 = 95.5\%$ , n=6, N=100,733) and severe illness (OR 4.91, 95%) 317 CI 1.35 – 8.47,  $I^2 = 0.0\%$ , n=4, N=333) among older-aged COVID-19 patients than younger ones 318 319 were even much greater when age was treated as  $\geq 60 vs < 60$  (Fig 6).

Fig 6. Forest plot showing the relationship of age with the odds of death, severe illness and admission in ICU among COVID-19 patients.

# 323 Gender

324	Fifty-two studies examined the effect of gender on the odds of death (n=16), severe illness
325	(n=32) and admission to ICU among COVID-19 patients (n=6). Out of 16 studies which
326	compared the odds of death between males and females, 10 reported increased odds in males and
327	six documented similar odds between males vs female. A meta-analysis of the 16 studies showed
328	increased odds of death among males than females (OR 1.34, 95% CI 1.18 – 1.50, $I^2 = 38.7\%$ ,
329	n=16, N=68,609). Similarly, of the 32 studies which compared the odds of severe illness
330	between males vs females, 11 reported increased odds and 21 studies document similar odds
331	between males vs female. A summary analysis of the 32 studies showed increased odds of severe
332	illness among males than females (OR 1.35, 95% CI 1.23 – 1.47, I <sup>2</sup> =0.0%, n=32, N=13,426);
333	however, this could not be further assessed by tandem risk factors (e.g., underlying
334	cardiovascular disease) in the available data.
335	There were six studies that examined the relationship of gender with the odds of
336	admission to ICU. Out of these six studies, two showed increased odds of admission to ICU in
337	males than females, but four studies showed a lack of association between gender and the odds
338	of admission to ICU. A summary of the 6 studies showed a lack of correlation between gender
339	and admission to ICU in COVID-19 patients (OR 1.52, 95% CI $0.69 - 2.36$ , $I^2 = 2.9\%$ , n=6,
340	N=666) (Fig 7).
341	Fig 7. Forest plot showing the relationship of gender with the odds of death, severe illness and
342	admission in ICU among COVID-19 patients.

343

344

## 345 Heterogeneity assessment

There was no heterogeneity ( $I_2 = 0.0\%$ ) observed among the studies included in the meta-346 347 analyses that estimated the summary odds ratio of death, severe illness or admission to ICU among COVID-19 patients with cerebrovascular diseases, chronic liver disease, chronic kidney 348 disease, cancer or smoker vs those without these comorbidities. There was also no or low 349 heterogeneity among the studies included in the meta-analyses that examined correlation of 350 351 clinical outcomes in COVID-19 patients with cardiovascular disease (I2=0.0% for death and 352 admission to ICU, I2=30.6% for severe illness), diabetes (I2=0.0% for admission to ICU, 353 I2=24.9% for severe illness), chronic respiratory disease (I2=0.0% for death and admission to ICU, I2=27.0% for severe illness ), age in years > 65 vs  $\leq$  65 (I2= 18.2% for death, I2=24.5% for 354 355 severe illness), and gender (I2=0.0% for severe illness, I2=2.9% for admission to ICU, 356 I2=38.7% for death). The heterogeneity level in meta-analyses performed to examine 357 associations of hypertension with the odds of death (I2=52.6%) and severe illness (I2=47.8%) 358 among COVID-19 patients was moderate.

However, heterogeneity was high among the studies combined in the meta-analyses to 359 examine the association of death with diabetes ( $I^2 = 67.4\%$ ) and age,  $\ge 60$  vs < 60 years ( $I^2 =$ 360 95.5%) in COVID-19 patients. Studies that were included in the meta-analyses to assess the 361 nature of the relationship of admission to ICU with hypertension ( $I^2 = 79.2\%$ ) also had high 362 heterogeneity. Subgroup analyses by study design dropped heterogeneity: diabetes ( $I^2 = 0.0\%$  in 363 retrospective), and age ( $I^2 = 0.0\%$  in retrospective;  $I^2 = 0.0\%$  in cross-sectional). Due to the few 364 numbers of studies that reported results on the effect of hypertension on the risk of admission to 365 366 ICU, we didn't perform subgroup analyses by study region/country or study design. Removal of

a study by Guan et al. 2020a [6], however, significantly minimized the heterogeneity of the studies that examined the effect of hypertension on the risk of admission to ICU ( $I^2 = 1.0\%$ ). On the other hand, the meta regression showed lack of effect of study area or country (meta regression coefficient ( $\beta$ )= -0.50, *P*= 0.073), study design ( $\beta$  = -0.23, *P*= 0.400) and

- sample size (1.25e-06, P=0.912) on the log ORs of death among COVID-19 patients with
- diabetes vs those without this problem. Similarly, study area or country ( $\beta = -0.30$ , P = 0.380),

study design ( $\beta = \beta = -0.04$ , P = 0.863) and sample size ( $\beta = 8.74e-06$ , P = 0.631) didn't

- significantly predict the log ORs of admission to ICU among COVID-19 patients of age  $\geq 60$
- 375 years vs < 60 years in the meta regression model.

## 376 **Publication bias assessment**

- 377 Odds ratio distributions against their standard error estimates and Egger tests for asymmetry did
- not indicate significant publication bias: hypertension (bias 6.22, *P*=0.11), diabetes (bias 1.43,
- P=0.634), cardiovascular disease (bias 1.64, P=0.71), chronic respiratory diseases (bias 6.47,
- P=0.13), chronic kidney disease (bias 88.99, P=0.11), and cancer (Egger's regression test (bias) -
- 0.26, P=0.953 (Fig 8 and S6 Fig). Funnel plots of odds ratios of the likelihood of developing
- severe *vs* moderate or mild illness among COVID-19 patients and their Egger tests also were not
- significant: hypertension (bias 5.05, *P*=0.21); diabetes (bias 3.29, *P*=0.353), chronic respiratory
- diseases (bias -8.36, *P*=0.12); chronic kidney disease (bias -0.57, *P*=0.807); and, cancer (bias
- 385 3.34, *P*=0.598) (Fig 8 and S6 Fig). Studies comparing the odds ratio of admission to ICU vs not
- admission to ICU among COVID-19 patients with cancer (bias -6.27, *P*=0.51), hypertension
- 387 (bias -5.36, *P*=0.12), diabetes (bias 0.53, P=0.763), cardiovascular (bias 1.37, *P*=0.40), chronic
- respiratory diseases (bias 1.98, P=0.67) were also spread evenly on both sides of the average OR

estimates, creating an approximately symmetrical funnel-shaped distribution (Fig 8 and S6 Fig).

- 390 The odds ratio estimates of the studies which examined the relationship of chronic liver disease
- (bias 0.47, *P*=0.752), cerebrovascular diseases (bias -5.83, *P*=0.395) and smoking behavior (bias
- 0.98, P=0.217) with severe illness or death in COVID-19 patients also had approximately
- 393 symmetrical funnel-shaped distribution and the Egger's test for the asymmetry of the plots were
- not significant (S6 Fig). However, there was publication bias among the studies comparing the
- odds of i) death vs survival in patients with age > 65 vs  $\leq$  65 years (bias 11.29, P=0.062) and

males *vs* females (bias 2.90, *P*=0.046); ii) severe *vs* mild or moderate illness in patients with age

 $500 > 65 vs \le 65$  years (bias 14.63, P=0.032), males vs females (bias 2.18, P=0.039) and those with

cardiovascular disease vs without having this problem (bias 5.62, P=0.0.034), the odds ratio

estimates scattered asymmetrically in the funnel plot (Fig 8 and S6 Fig).

400 Fig 8. Funnel plots showing the odds ratio of death, severe illness and admission in ICU against the

401 standard errors based on comorbidity and age

### 402 **Risk of bias and quality of the studies**

The study's risk of bias and quality included in this study is summarized in the supplementary 403 404 table (S4 table). Out of the 71 studies, 54 were moderate quality, and 18 were good quality in recruiting the study participants. The majority of the studies also used good (n=54) or moderate 405 406 quality (n=17) reliable and valid tools to determine COVID-19 severity status and related deaths 407 among the study participants. In many studies (n=44), the researchers or data collectors were not 408 aware of the group (exposed vs. unexposed) to which the study participants belong in the data 409 collection process and/or the participants were blinded about the research question. About 2/3 of 410 the included studies were of moderate quality in terms of the study design (retrospective casecontrol or cohort) and controlling confounders that may affect the relationship between 411

412 comorbidities and COVID-19 related outcomes or death. On the other hand, several studies rated 413 as low quality based on study design (n=15), data collection (n=8), confounders (n=26), blinding 414 (n=28) and dropouts and withdrawals (n=29). None of the studies were of low quality in terms of 415 blinding of the outcome assessor and the study participants. Total rating using the six criteria 416 showed that 14 studies were of strong quality, 23 studies were of moderate quality, and 34 417 studies were rated as low quality. Studies were included in this review, regardless of their 418 qualities.

## 419 **Discussion**

420 The current systematic review and meta-analysis confirmed the correlation of demographic 421 factors and comorbidities with severe illness and death among COVID-19 patients, as reported in 422 other reviews [11-13]. COVID-19 patients who were males, with age >60 or 65 years and those who had hypertension, diabetes, cardiovascular disease, chronic respiratory disease and 423 424 cerebrovascular diseases, were found more susceptible to death. The risk of developing severe 425 illness also increased among males COVID-19 patients of ages older than 60 or 65 years, and 426 those who had hypertension, diabetes, and cardiovascular diseases. However, comorbidities, 427 including cancer, chronic kidney and chronic liver diseases, were not associated with severe 428 illness and mortality in COVID-19 patients.

429 Chronic diseases, including hypertension, diabetes, chronic respiratory disease, 430 cardiovascular disease put the body in stress for a longer period of time. This stress can weaken 431 the immune system. For example, diabetes can cause damage to  $\beta$ -cell through the release of 432 inflammatory cytokines such as IL-1 $\beta$  and TNF $\alpha$  that [90]. Metabolic disorders may also impair 433 macrophage and lymphocyte function leading to low immune function [39]. Chronic disease can

434 also affect the function of different organs of the body such as the lung, heart, vascular tube. 435 These organs dysfunction and low immunity due to the chronic diseases will complicate and increase the risk of severe illness and death during SARS-CoV-2 infection. It is also possible that 436 437 angiotensin converting enzyme inhibitors or angiotensin receptor blockers used to treat diabetes, hypertension, or heart disease may upregulate Angiotensin converting enzyme 2, a receptor to 438 439 SARS-CoV-2 in the host cell [91-93]. This may facilitate the viral multiplication within the host 440 cell, though this is controversial [94]. Similarly, immunity can decrease with age, which will make older patients vulnerable to 441 442 develop severe illness and death during SARS-CoV-2 infection. While functional 443 immunosuppression of senescence may play a role in older adults experiencing worse disease, older adults also are more likely to have an underlying chronic disease. Males may also be more 444 likely to involve in risky behaviors, including smoking, alcohol drinking and drug use, which can 445 down-regulate the immune response against the SARS-CoV-2 infection. 446 447 Lack of association of some chronic diseases (e.g., kidney disease) and smoking with COVID-19 outcomes could be due to limitations in the original studies. The role of chronic 448 kidney disease was assessed among comparatively few participants, which could explain its 449

450 discordance with the results among cardiovascular equivalents. Potential ascertainment bias in

the original studies could also partly explain the lack of association of chronic respiratory disease

452 with severe illness though the disease showed to have a role in death and admission to ICU.

453 Similarly, lack of correlation of smoking with clinical outcomes in the COVID-19 patients could

454 be due the watering effect of the chronic disease outcomes. If most of the patients with

455 cardiopulmonary diseases were smokers, exacerbated by ascertainment bias (they did not ask

456 enough, or misinterpreted prior smoking and current smoking from never smoking), could miss

the distinction of tobacco use. Unfortunately, most studies didn't control chronic disease as apotential confounder when examining the role of smoking on COVID-19 related outcomes.

459 These findings have a number of public health and research implications that will help in 460 the management of high-risk COVID-19 patients to mitigate the progression of the disease and associated death. Based on our findings, special strategies are warranted to prevent SARS-CoV-2 461 462 infection and manage COVID-19 cases with underlying comorbidities, particularly older age 463 males' patients. For example, creating awareness and provision of robust personal protection measures would be needed to prevent older aged individuals who have comorbidities from 464 465 SARS-CoV-2 infection. Second, more intensive surveillance and early hospital referral would be 466 important for older age males COVID-19 patients with comorbidities. When these high-risk older age COVID-19 patients, particularly those with comorbidities, are admitted to a hospital, 467 468 special attention and treatment care could be considered to prevent further progression of the 469 disease and death. Third, future vaccination intervention against SARS-CoV-2 infection should be formulated to better protect people with comorbidities. In addition, when the SARS-CoV-2 470 471 vaccination is available, people with hypertension, cardiovascular disease, diabetes, respiratory 472 system disease and cerebrovascular disease should be a priority in the vaccination 473 recommendations. The current findings also suggest prospective cohort studies with adequate 474 power to verify whether and how comorbidities and demographics can affect the risk of acquisition of the SARS-CoV-2 and clinical outcomes of the disease. 475

This meta-analysis has a number of strengths. Unlike previous meta-analyses on the related topic [11-13], it i) involves a comprehensive analysis of a large number of studies based in China, South Korea, Iran, Europe and North America; ii) summarized the literature on the effect of comorbidities, including cancer, chronic liver and cerebrovascular disease with severe

480 illness and death; and iii) compared the risk of admission to ICU vs not among hospitalized 481 COVID -19 patients stratified based on comorbidities and demographic status. In addition, we 482 found little publication bias regarding the examination of the association of comorbidities with 483 severe illness and death in COVID-19 patients. Most of our meta-analyses had no or low heterogeneity, including the association of cardiovascular disease, chronic respiratory disease, 484 chronic liver, cerebrovascular disease, chronic kidney disease, age, gender and severe illness and 485 486 death. Although there was a high level of heterogeneity in studies that examined the correlation of diabetes with severe illness, subgroup analysis by the study design significantly decreased the 487 488 heterogeneity. Variation in the study participant inclusion criteria and the methods used for examining comorbidities among the studies could have also contributed to the observed high 489 heterogeneity. 490

491 However, the calculated summary OR in the current meta-analyses could have been 492 affected due to limitations in the original studies. Most studies reported frequencies or crude estimates which were not adjusted for potential confounder that could affect the relationship 493 494 between comorbidities and the risk of severe illness or death in COVID-19 patients. In addition, 495 the sample size and/or the number of severe cases or deaths in patients with varied comorbidity 496 or demographic status were small in some studies, increasing the confidence interval estimates for the OR and decreasing the power to reject false associations. These limitations in the original 497 studies could have under or overestimated the summary OR estimates of the meta-analysis that 498 499 examined the relationship of demographic and comorbidities with this review's outcomes. 500 Moreover, due to the cross-sectional and retrospective nature of the original studies, we cannot make firm conclusions that the observed higher odds of severe illness and death among COVID-501 19 patients were due to comorbidities, their demographic status, or other undetermined factors, 502

though this was mitigated with the incorporation of random effects. In addition, as the majority of the studies included in the meta analysis were retrospective, we didn't assess the risk of selection bias. Furthermore, in order to decrease the risk of misclassification bias, the exposures cardiovascular diseases, diabetes and cerebrovascular diseases could be merged while examining their effect on the risk of death and severe illness. However, the studies assessed and reported the results for these exposures differently, separately.

# 509 **Conclusions**

In conclusion, older age and the presence of comorbidities or chronic diseases increase the risk of developing severe illness, admission to ICU and death among COVID-19 patients. Special strategies are warranted to prevent SARS-CoV-2 infection and manage COVID-19 cases with underlying comorbidities, particularly older age male patients, though the impact in women may be insufficiently observed. Prospective, longitudinal studies that control confounders are needed to assess strategies for mitigating severe illness, admission to ICU, and death in COVID-19

516 patients.

Funding. This work has not received support from an external funding source. The work is thatof the authors, and does not necessarily reflect the views of any agency of the State of Nebraska.

519 **Competing interests**: The authors declare that they have no competing interests

520

521

522

1. WHO Coronavirus Disease (COVID-19) Dashboard. Available in

# 523 **References**

524

525		https://covid19.who.int/ on September 2, 2020.
526	2.	Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of
527		COVID-19. Nature. 2020; 583: 437- 440.
528	3.	Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
529		and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
530		Area. JAMA. 2020;323(20):2052-2059.
531	4.	Liua Y, Gua Z, Xi S, et al. What are the underlying transmission patterns of COVID-19
532		outbreak? An age-specific social contact characterization. EClinical Medicine.
533		2020;22:100354.
534	5.	Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients
535		with COVID-19. Crit Care. 2020;24(1):179.
536	6.	Guan WJ, Liang WH, Zhao Y et al. Comorbidity and its impact on 1590 patients with
537		Covid-19 in China: A Nationwide Analysis. Eur Respir J . 2020; 55: 2000547.
538	7.	Li X, Xu S, Yu M et al. Risk factors for severity and mortality in adult COVID-19
539		inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146: 110-118.
540	8.	Guan WJ, Ni ZY, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in
541		China. N Engl J Med. 2020;382(18):1708-1720.
542	9.	Hu H, Yao N, Qiu Y. Comparing rapid scoring systems in mortality prediction of critical
543		ill patients with novel coronavirus disease. Acad Emerg Med. 2020; 27: 461-468.
544	10	. Du RH, Liu LM, Yin W et al. Hospitalization and Critical Care of 109 Decedents with
545		COVID-19 Pneumonia in Wuhan, China. Ann Am Thorac Soc. 2020;17: 839–846.

546	11. Li X, Guan B, Su T, et al. Impact of cardiovascular disease and cardiac injury on in-
547	hospital mortality in patients with COVID-19: a systematic review and meta-analysis.
548	Heart. 2020; 106(15): 1142-1147.
549	12. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan
550	coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect
551	Dis. 2020; 94:91-95.
552	13. Zheng Z, Peng F, Xu B, et al. Risk factors of critical and mortal COVID-19 cases: A
553	systematic literature review and meta-analysis. J Infect. 2020; 11:15.
554	14. Dorjee K, Hyunju Kim. Epidemiological Risk Factors Associated with Death and Severe
555	Disease in Patients Suffering From COVID-19: A Comprehensive Systematic Review
556	and Meta-analysis. doi: https://doi.org/10.1101/2020.06.19.20135483.
557	15. Bellou V, Tzoulaki I, Evangelou E, Belbasis L. Risk factors for adverse clinical
558	outcomes in patients with COVID-19: A systematic review and meta-analysis.
559	https://doi.org/10.1101/2020.05.13.20100495
560	16. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting
561	Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med
562	2009; 6(6): e1000097.
563	17. Degarege A, Naveed Z, Kabayundo J. Risk factors for severe illness and death in
564	COVID-19: a systematic review and meta-analysis. PROSPERO 2020 CRD42020184440
565	Available in
566	https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020184440.
567	Accessed on July 6, 2020.

568	18. NIH.	COVID-19	treatment	guidelines.	Management	of Persons	with	COVID-	·19.
					<b>1</b> )				

- 569 Available at: https://www.covid19treatmentguidelines.nih.gov/overview/management-of-
- 570 covid-19/. Accessed on August 5, 2020.
- 571 19. Effective Public Health Practice Project. Quality assessment tool for quantitative studies.
- 572 Hamilton, ON: Effective public health practice project. Available from:
- 573 <u>https://merst.ca/ephpp</u>. Accessed on 11/20/2020.
- 574 20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta575 analyses. BMJ 2003; 327.
- 576 21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.

577 1986;7:177–88.

- 578 22. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI; Health Outcomes, Policy,
- and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-
- analysis: the role of meta-regression. Int J Clin Pract. 2009;63(10):1426-1434.
- 581 23. Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical
  582 tests for publication bias. J Epidemiol. 2005;15(6):235–43.
- 583 24. Characteristics of Health Care Personnel with COVID-19 United States, February 12-

584 April 9, 2020. MMWR Morb Mortal Wkly Rep . 2020;69(15):477-481.

- 585 25. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions
- 586 Among Patients with Coronavirus Disease 2019 United States, February 12-March 28,
- 587 2020. MMWR Morb Mortal Wkly Rep . 2020;69(13):382-386.
- 26. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical
- 589 features, laboratory characteristics, and outcomes of patients hospitalized with

590	coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis
591	(Berl). 2020;7(2):91-96.

- 592 27. Al-Rousan N, Al-Najjar H. Data Analysis of Coronavirus CoVID-19 Epidemic in South
- 593 Korea Based on Recovered and Death Cases. J Med Virol. 2020; doi: 10.1002/jmv.25850
- 28. Bezzio C, Saibeni S, Variola A et al. Outcomes of COVID-19 in 79 patients with IBD in
- 595 Italy: an IG-IBD study. Gut. 2020;69(7):1213-1217.
- 596 29. Bi Q, Wu Y, Mei S et al. Epidemiology and transmission of COVID-19 in 391 cases and
- 5971286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet
- 598 Infect Dis. 2020;20(8):911-919.
- 30. Bi X, Su Z, Yan H et al. Prediction of severe illness due to COVID-19 based on an
  analysis of initial Fibrinogen to Albumin Ratio and Platelet count. Platelets.
- 601 2020;31(5):674-679
- 31. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected
- 603 Underlying Health Conditions Among Patients with Coronavirus Disease 2019 United
- 604 States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep . 2020;69(13):382605 386.
- 32. Chen Q, Zheng Z, Zhang C et al. Clinical characteristics of 145 patients with corona virus
   disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection .48(4):543-551
- 33. Colaneri M, Sacchi P, Zuccaro V et al. Clinical characteristics of coronavirus disease
- 609 (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to February
- 610 28 2020. Euro Surveill . 2020;25(16):10.2807/1560-7917.ES.2020.25.16.2000460.

611	34. Deng Q, Hu B, Zhang Y et al. Suspected myocardial injury in patients with COVID-19:
612	Evidence from front-line clinical observation in Wuhan, China. Int J Cardiol . 2020;
613	311:116-121.
614	35. Du RH, Liang LR, Yang CQ et al. Predictors of Mortality for Patients with COVID-19
615	Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur Respir J . 2020;
616	55(5):2000524.
617	36. Dudley JP, Lee NT. Disparities in Age-Specific Morbidity and Mortality from SARS-
618	CoV-2 in China and the Republic of Korea. Clin Infect Dis . 2020; 71(15):863-865.
619	37. Feng Y, Ling Y, Bai T et al. COVID-19 with Different Severity: A Multi-center Study of
620	Clinical Features. Am J Respir Crit Care Med . 2020; 201(11):1380-1388.
621	38. Gong J, Ou J, Qiu X et al. A Tool to Early Predict Severe Corona Virus Disease 2019
622	(COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong,
623	China. Clin Infect Dis . 2020; 71(15):833-840.
624	39. Grasselli G, Zangrillo A, Zanella A et al. Baseline Characteristics and Outcomes of 1591
625	Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
626	JAMA . 2020; 323(16):1574-1581.
627	40. Guo W, Li M, Dong Y et al. Diabetes is a risk factor for the progression and prognosis of
628	COVID-19. Diabetes Metab Res Rev. 2020; e3319. doi: 10.1002/dmrr.3319
629	41. Han H, Xie L, Liu R et al. Analysis of heart injury laboratory parameters in 273 COVID-
630	19 patients in one hospital in Wuhan, China. J Med Virol . 2020; 92(7):819-823.
631	42. Hu L, Chen S, Fu Y et al. Risk Factors Associated with Clinical Outcomes in 323
632	COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis . 2020; ciaa539. doi:
633	10.1093/cid/ciaa539.

634	43. Ji D, Zhang D, Xu J et al. Prediction for Progression Risk in Patients with COVID-19
635	Pneumonia: the CALL Score. Clin Infect Dis . 2020; 71(6):1393-1399.
636	44. Kalligeros M, Shehadeh F, Mylona EK et al. Association of Obesity with Disease
637	Severity among Patients with COVID-19. Obesity (Silver Spring) . 2020; 28(7):1200-
638	1204.
639	45. Lei F, Liu YM, Zhou F et al. Longitudinal association between markers of liver injury
640	and mortality in COVID-19 in China. Hepatology. 2020; 72(2):389-398.
641	46. Leung C. Risk factors for predicting mortality in elderly patients with COVID-19: a
642	review of clinical data in China. Mech Ageing Dev. 2020:111255.
643	47. Li K, Wu J, Wu F et al. The Clinical and Chest CT Features Associated With Severe and
644	Critical COVID-19 Pneumonia. Invest Radiol. 2020;55(6):327-331.
645	48. Lian J, Jin X, Hao S et al. Analysis of Epidemiological and Clinical features in older
646	patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis .
647	2020; doi: 10.1093/cid/ciaa242.
648	49. Lin L, Jiang X, Zhang Z et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2
649	infection. Gut. 2020; 69(6):997-1001.
650	50. Liu Y, Du X, Chen J et al. Neutrophil-to-lymphocyte ratio as an independent risk factor
651	for mortality in hospitalized patients with COVID-19. J Infect . 2020; 81(1):e6-e12.
652	51. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug
653	Therapy, and Mortality in Covid-19. N Engl J Med. 2020; 382(25):e102.
654	52. Mehta V, Goel S, Kabarriti R et al. Case Fatality Rate of Cancer Patients with COVID-19
655	in a New York Hospital System. Cancer Discov. 2020; 10(7):935-941.

656	53. Middeldorp S, Coppens M, van Haaps TF et al. Incidence of venous thromboembolism in
657	hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18(8):1995-2002.
658	54. Nikpouraghdam M, Jalali Farahani A, Alishiri G et al. Epidemiological characteristics of
659	coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin
660	Virol . 2020;127:104378.
661	55. Pei G, Zhang Z, Peng J et al. Renal Involvement and Early Prognosis in Patients with
662	COVID-19 Pneumonia. J Am Soc Nephrol. 2020; 31(6):1157-1165.
663	56. Pereira MR, Mohan S, Cohen DJ et al. COVID-19 in Solid Organ Transplant Recipients:
664	Initial Report from the US Epicenter. Am J Transplant . 2020; 20(7):1800-1808.
665	57. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with COVID-
666	19 in Wuhan, China. Clin Infect Dis . 2020; 71(15):762-768.
667	58. Qu R, Ling Y, Zhang YH et al. Platelet-to-lymphocyte ratio is associated with prognosis
668	in patients with coronavirus disease-19. J Med Virol . 2020; 10.1002/jmv.25767. doi:
669	10.1002/jmv.25767.
670	59. Richardson S, Hirsch JS, Narasimhan M et al. Presenting Characteristics, Comorbidities,
671	and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
672	Area. JAMA . 2020; 323(20):2052-2059.
673	60. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-
674	19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care.
675	2020;24(1):108-020-2833-7.
676	61. Simonnet A, Chetboun M, Poissy J et al. High prevalence of obesity in severe acute
677	respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical
678	ventilation. Obesity (Silver Spring) . 2020; 28(10):1994.

- 679 62. Sun L, Shen L, Fan J et al. Clinical Features of Patients with Coronavirus Disease 2019
- 680 (COVID-19) from a Designated Hospital in Beijing, China. J Med Virol. 2020;
- 681 10.1002/jmv.25966. doi: 10.1002/jmv.25966.
- 682 63. Sun S, Cai X, Wang H et al. Abnormalities of peripheral blood system in patients with

683 COVID-19 in Wenzhou, China. Clin Chim Acta . 2020;507:174-180.

- 64. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with
  decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J
- 686 Thromb Haemost . 2020;18(5):1094-1099.

687 65. Tedeschi S, Giannella M, Bartoletti M et al. Clinical impact of renin-angiotensin system

688 inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-

- 689 19. Clin Infect Dis. 2020; 71(15):899-901.
- 66. Tian S, Hu N, Lou J et al. Characteristics of COVID-19 infection in Beijing. J Infect.
  2020;80(4):401-406.
- 692 67. To KK, Tsang OT, Leung WS et al. Temporal profiles of viral load in posterior
- oropharyngeal saliva samples and serum antibody responses during infection by SARS-
- 694 CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-574.
- 695 68. Verity R, Okell LC, Dorigatti I et al. Estimates of the severity of coronavirus disease
- 696 2019: a model-based analysis. Lancet Infect Dis . 2020; 20(6):669-677.
- 697 69. Wan S, Xiang Y, Fang W et al. Clinical features and treatment of COVID-19 patients in
  698 northeast Chongqing. J Med Virol . 2020; 92(7):797-806.
- 699 70. Wang D, Yin Y, Hu C et al. Clinical course and outcome of 107 patients infected with the
- novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit
- 701 Care . 2020;24(1):188-020-02895-6.

702	71. Wang J, Xu Z, Wang J et al. CT characteristics of patients infected with 2019 novel
703	coronavirus: association with clinical type. Clin Radiol . 2020; 75(6):408-414.
704	72. Wang L, He W, Yu X et al. Coronavirus disease 2019 in elderly patients: Characteristics
705	and prognostic factors based on 4-week follow-up. J Infect . 2020; 80(6):639-645.
706	73. Wei X, Su J, Yang K et al. Elevations of serum cancer biomarkers correlate with severity
707	of COVID-19. J Med Virol . 2020.
708	74. Wu J, Li W, Shi X et al. Early antiviral treatment contributes to alleviate the severity and
709	improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern
710	Med . 2020; 10.1002/jmv.25957. doi: 10.1002/jmv.25957.
711	75. Yan Y, Yang Y, Wang F et al. Clinical characteristics and outcomes of patients with
712	severe covid-19 with diabetes. BMJ Open Diabetes Res Care .
713	2020;8(1):10.1136/bmjdrc-2020-001343.
714	76. Yang G, Tan Z, Zhou L et al. Effects Of ARBs And ACEIs On Virus Infection,
715	Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension:
716	A Single Center Retrospective Study. Hypertension . 2020; 76(1):51-58.
717	77. Yang R, Gui X, Zhang Y, Xiong Y. The role of essential organ-based comorbidities in
718	the prognosis of COVID-19 infection patients. Expert Rev Respir Med . 2020; 14(8):835-
719	838.
720	78. Yang X, Yang Q, Wang Y et al. Thrombocytopenia and its association with mortality in
721	patients with COVID-19. J Thromb Haemost. 2020; 18(6):1469-1472.
722	79. Yao Q, Wang P, Wang X et al. Retrospective study of risk factors for severe SARS-Cov-
723	2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020; 130(5):390-399.

724	80. Yu X, Sun X, Cui P et al. Epidemiological and Clinical Characteristics of 333 Confirmed
725	Cases with Coronavirus Disease 2019 in Shanghai, China. Transbound Emerg Dis. 2020;
726	67(4):1697-1707.
727	81. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics
728	and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan,
729	China: a retrospective analysis. Respir Res . 2020;21(1):74-020-01338-8.
730	82. Zhang J, Liu P, Wang M et al. The clinical data from 19 critically ill patients with
731	coronavirus disease 2019: a single-centered, retrospective, observational study. Z
732	Gesundh Wiss . 2020; 21;1-4. doi: 10.1007/s10389-020-01291-2.
733	83. Zhang R, Ouyang H, Fu L et al. CT features of SARS-CoV-2 pneumonia according to
734	clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan
735	city. Eur Radiol. 2020; 30(8):4417-4426.
736	84. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19
737	patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China.
738	Liver Int . 2020; 40(9):2095-2103.
739	85. Zheng KI, Gao F, Wang XB et al. Obesity as a risk factor for greater severity of COVID-
740	19 in patients with metabolic associated fatty liver disease. Metabolism . 2020:154244.
741	86. Zou Y, Guo H, Zhang Y et al. Analysis of coagulation parameters in patients with
742	COVID-19 in Shanghai, China. Biosci Trends . 2020;14(4):285-289.
743	87. Chen R, Liang W, Jiang M. Risk factors of fatal outcome in hospitalized subjects with
744	coronavirus disease 2019 from a nationwide analysis in china. Chest 2020; 158(1): 97-
745	105.

- 88. Yuanyuan Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in
  china. Pediatrics, 2020; 145:e20200702
- 748 89. CDC. COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus
- 749 Disease 2019 (COVID-19) —United States, February 12–March 16. 2020 (MMWR)
- 750 2020; 69: 12
- 90. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity.
  Cold Spring Harbor Perspect Med 2012;2:a007724.
- 753 91. Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;126(10):1443-1455.
- 754 92. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease.
- 755 Circulation. 2020;141(20):1648-1655.
- 93. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular
- consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-H1090.
- 94. Dhawan R, Gundry RL, Brett-Major DM, et al. COVID-19 and cardiovascular disease:
- 759 What we know, what we think we know, and what we need to know. J Mol Cell Cardiol.
- 760 2020;144:12-14.
- 761
- 762
- 763
- 764
- 765

## 767 **Supporting information**

- 768 S1 Table. PRISMA 2009 Checklist.
- 769 S2 Table. Searching details Embase.
- 770 S3 Table. Characteristics of the studies.
- 771 S4 Table. Risk of bias and quality of the studies included in this review.
- 572 S1 Fig. Forest plot showing the relationship of cancer with the odds of death, severe illness and
- admission in ICU among COVID-19 patients.
- S2 Fig. Forest plot showing the relationship of chronic Kidney disease with the odds of death,
- severe illness and admission in ICU among COVID-19 patients.
- <sup>776</sup> S3 Fig. Forest plot showing the relationship of chronic liver disease with the odds of death,
- severe illness and admission in ICU among COVID-19 patients.
- 778 S4 Fig. Forest plot showing the relationship of Cerebrovascular disease with the odds of death, severe
- illness and admission in ICU among COVID-19 patients.
- 780 S5 Fig. Forest plot showing the relationship of smoking with the odds of death, severe illness and
- admission in ICU among COVID-19 patients.
- S6 Fig. Funnel plots showing the odds ratio of death, severe illness and admission in ICU against
- the standard errors based on comorbidity and age status.

784



Fig 1.

Author, year, Ref.		% OR (95% Cl) W	sample size /eight (study desigi
Death vs survival Deng et al., 2020 [5] Du et al., 2020 [39] Guan et al., 2020 [39] Guan et al., 2020 [6] Liu et al., 2020 [50] Nikpouraghdam et al., 2020 [54] Tedeschi et al., 2020 [65] Wang et al., 2020 [70] Wang et al., 2020 [72] Yan et al., 2020 [77] Yao et al., 2020 [79] Hu et al., 2020 [9] Subtotal (I-squared = 52.6%, p = 0.013)		3.04 (2.56, 3.62) 19 4.08 (1.58, 10.50)1 2.24 (1.70, 2.95) 10 6.86 (3.85, 12.19)2 3.94 (1.82, 8.53) 3 1.81 (0.85, 3.87) 10 4.31 (2.91, 6.39) 8 5.00 (1.74, 14.30)1 1.53 (0.89, 2.64) 19 4.81 (2.48, 9.35) 3 1.68 (0.67, 4.21) 8 13.53 (3.55, 51.50) 1.34 (0.45, 3.96) 8 2.60 (1.95, 3.25) 10	9.06 44672 (CS) 95 179(P) 8.17 1591 (R) 21 1590 (CS) 23 245 (R) 0.07 2968 (R) 56 609 (R) 03 107 (R) 5.67 393 (R) 10 193 (R) 39 462 (R) 07 108 (R) 47 105 (R) 00.00 53222
Severe illness vs moderate/mild Chen et al., 2020 [32] Colaneri et al., 2020 [33] Deng et al., 2020 [34] Feng et al., 2020 [37] Guan et al., 2020 [6] Hu et al., 2020a [6] Hu et al., 2020b [47] Pei et al., 2020b [47] Pei et al., 2020b [47] Pei et al., 2020b [55] Pereira et al., 2020 [56] Qin et al., 2020 [56] Qin et al., 2020 [67] Sun et al., 2020 [67] Wan et al., 2020 [69] Wei et al., 2020 [73] Yang et al., 2020 [76] Zhang et al., 2020 [83] Yu et al., 2020 [60] Du et al., 2020 [60] Du et al., 2020a [10] Subtotal (l-squared = 47.8%, p = 0.008)		$\begin{array}{c} 1.81 \ (0.71, 4.62) \ 3.\\ 0.70 \ (0.19, 2.61) \ 5.\\ 1.53 \ (0.67, 3.51) \ 4.\\ 1.82 \ (1.15, 2.87) \ 7.\\ 3.37 \ (2.50, 4.57) \ 6.\\ 1.78 \ (1.11, 2.88) \ 7.\\ 1.59 \ (0.24, 10.18) 0.\\ 2.20 \ (1.51, 3.20) \ 8.\\ 1.71 \ (1.06, 2.76) \ 8.\\ 1.66 \ (0.64, 4.38) \ 3.\\ 2.62 \ (1.65, 4.17) \ 5.\\ 12.60 \ (2.18, 73.40).\\ 3.66 \ (0.51, 26.20) 0.\\ 1.06 \ (0.30, 3.67) \ 3.\\ 2.10 \ (1.22, 3.60) \ 5.\\ 1.13 \ (0.65, 1.98) \ 9.\\ 10.70 \ (3.56, 32.19).\\ 0.70 \ (0.20, 2.00) \ 7.\\ 22.00 \ (6.03, 80.30).\\ 5.65 \ (3.05, 10.45) 1.\\ 0.80 \ (0.37, 1.73) \ 9.\\ 1.70 \ (1.30, 2.10) \ 10.\\ \end{array}$	17       145 (R)         89       44 (R)         91       112 (R)         99       476 (CS)         87       1590 (CS)         82       323 (R)         .62       83 (CS)         .09       548 (R)         .06       333 (CS)         .39       90 (R)         .64       452 (R)         .01       55 (CS)         .93       135 (CS)         .99       252 (R)         .36       462 (R)         .08       120 (R)         .72       333 (CS)         .01       111 (CS)         .08       487 (CS)         .26       109 (R)         .00.00       6172
Admitted vs not admitted to ICU Aggarwal et al. 2020 [26] Guan et al., 2020a [6] Kalligeros et al., 2020 [44] Simonnet et al., 2020 [64] Subtotal (I-squared = 79.2%, p = 0.002)		0.20 (0.02, 1.71) 30 3.39 (2.21, 5.21) 24 0.79 (0.27, 2.28) 20 2.29 (0.89, 5.84) 10 1.50 (0.09, 2.90) 10	0.15 16 (CS) 4.45 1590 (CS) 8.85 103 (R) 6.55 123 (R) 00.00 <b>1832</b>
-2 0 1 2 Decreased Risk	I I 4 6 8 Increased Risk	CS cross-section ICU intensive concentration P prospective R retrospective	onal are unit

Fig 2.

Author year Bef		OR (95% CI)	% Weight	sample size (study design)
		01( (35 % 01)	vveigni	(study design
Death <i>vs</i> survival				
Deng ei al., 2020 [5]		5.42 (4.33, 6.79)	74.18	44672 (CS)
Du et al., 2020 [35]	→	11.06 (4.06, 30.06	)0.66	179 (P)
Guan et al., 2020a [6]◆		5.56 (2.48, 12.45)	4.52	1590 (CS)
Wang et al., 2020 [70]	$\longrightarrow$	7.97 (2.29, 27.75)	0.69	107 (R)
Wang et al., 2020 [72]		3.60 (1.90, 6.82)	18.55	393 (R)
Yan et al., 2020 [75]	$\longrightarrow$	6.75 (2.25, 20.16)	1.40	193 (R)
Subtotal (I-squared = 0.0%, p = 0.725)		5.16 (4.10, 6.22)	100.00	47134
Severe illness <i>vs</i> moderate/mild				
Colaneri et al., 2020 [33]		2.40 (0.59, 9.63)	4.68	44 (R)
Deng et al., 2020		2.01 (0.59, 6.77)	8.89	44672 (CS)
Feng et al., 2020 [37]		2.50 (1.27, 4.92)	18.27	476 (CS)
Guan et al., 2020a [6] —————		2.84 (1.62, 4.96)	20.11	1590 (CS)
Qin et al., 2020 [57]	>	4.97 (1.47, 19.79)	1.25	452 (R)
Wei et al., 2020 [73]		3.56 (1.25, 10.13)	4.83	252 (R)
Zhang et al., 2020 [83]	$\longrightarrow$	4.30 (1.07, 17.20)	1.59	120 (R)
Yu et al., 2020 [80]		4.20 (1.20, 14.20)	2.40	333 (CS)
Shi et al.,2020 [60]	$\longrightarrow$	5.47 (1.54, 19.41)	1.31	487 (CS)
Du et al., 2020a [10] 🔶		0.68 (0.30, 1.52)	36.67	109 (R)
Subtotal (I-squared = 30.6%, p = 0.16		2.04 (1.01, 3.08)	100.00	48535
Admitted vs not admitted to ICU				
Aggarwal et al., 2020 [26]	$\longrightarrow$	4.20 (0.33, 53.12)	0.02	16 (CS)
MMWR, 2020a [31]		1.33 (1.04, 1.71)	95.34	6637 (CS)
Guan et al., 2020a [6]		2.48 (1.14, 5.38)	2.38	1590 (CS)
Kalligeros et al., 2020 [44]		1.52 (0.47, 4.82)	2.26	103 (R)
Subtotal (I-squared = 0.0%, p = 0.761		1.36 (1.04, 1.69)	100.00	8346
r r				
		CS grass soctional		
-3 -2 0 1 4 8	14 16	ICU intensive care ur	it	
Decreased Risk Increased Risk		P prospective R retrospective		

Fig 3.



Fig 4.

Author, year, Ref							OR (95% CI)	% Weight	Sample size (study design)
Death vs survival									
Deng et al., 2020 [5]					<b>-</b>		2.91 (2.02, 4.18)	40.37	44672 (CS)
Guan et al., 2020a [6]						$\rightarrow$	11.53 (4.36, 30.45	) 0.28	1590 (CS)
Liu et al., 2020 [50]		•			•	$\longrightarrow$	4.14 (0.94, 18.22)	0.63	245 (R)
Mehra et al., 2020 [51]					<b>-</b>		2.88 (1.96, 4.23)	36.55	8910 (CS)
Nikpouraghdam et al., 2020 [54]				+			2.05 (0.99, 4.22)	18.05	2968 (R)
Wang et al., 2020 [72]				—		+>	5.37 (2.17, 13.29)	1.52	393 (R)
Yan et al., 2020 [75]		-			•	$\longrightarrow$	3.09 (0.83, 11.48)	1.66	193 (R)
Hu et al., 2020 [9]					•	$\longrightarrow$	4.00 (1.11, 15.50)	0.91	105 (R)
Li et al., 2020b [47]					_	$\longrightarrow$	10.86 (1.15, 102.7	09.02	548 (R)
Subtotal (I-squared = 0.0%, p = 0.881)				<	>		2.83 (2.14, 3.51)	100.00	59624
Severe illness vs moderate/mild									
Deng et al., 2020 [5]	-					$\longrightarrow$	2.06 (0.21, 20.48)	1.46	44672 (CS)
Feng et al., 2020 [37]				_		•>	5.47 (2.23, 13.39)	4.52	476 (CS)
Guan et al., 2020a [6]						$\longrightarrow$	9.25 (4.00, 21.38)	1.97	1590 (CS)
Li et al., 2020b [47]					•	$\longrightarrow$	3.49 (1.12, 10.84)	5.80	548 (R)
pereirs et al., 2020 [56]		_	-				1.35 (0.44, 4.12)	23.98	90 (R)
Qin et al., 2020 [57]				•			1.76 (0.47, 6.61)	12.38	452 (R)
Yu et al., 2020 [80]	-			-		$\longrightarrow$	2.00 (0.20, 18.30)	1.82	333 (CS)
Zhang et al., 2020					•	`	2.68 (0.23, 31,20)	0.64	111 (R)
Du et al., 2020a [10]	-	-					0.29 (0.08, 0.97)	47.43	109 (R)
Subtotal (I-squared = 27.0%, p = 0.204	) -	V			-		1.39 (0.15, 2.64)	100.00	48381
Admitted vs not admitted to ICI	,								
Addarwal et al. 2020 [26]	_		<u> </u>				1.00 (0.05, 19.36)	0 19	16 (CS)
MMWR 2020 [31]			_ <b></b>	_			1.50 (0.00, 10.00)	95 59	6637 (CS)
Guan at al. 2020 [61]			•				6.59 (2.66, 16.30)	0.30	1590 (CS)
Guan et al., 2020a [6]							1 50 (0 47 4 92)	2.00	1030 (CS) 102 (B)
Railigeros et al., $2020$ [44] Subtotal (Leguerod = 0.0% p = 0.542)			Ň				1.50 (0.47, 4.62)	3.02	103 (R) 8346
Subtoral (I-squared - 0.0%, p - 0.943)			$\sim$				1.52 (1.09, 1.94)	100.00	0340
I	1		1	ן י	1	6 7	CS cross-sectional		
-2	U		I	2	4	0 /	P prospective	nt	
Decreas	ed Ris	sk			Increased Risk		R retrospective		



Author, year, Ref Age in vears >65 vs ≤65		OR (95% Cl)	% Weight	sample size (study design)
Death vs survival Bezzio et al., 2020 [28] Du et al., 2020b [35] Mehra et al., 2020 [51] Yang et al., 2020 [77] Yao et al., 2020 [79] MMWR., 2020 [89] Subtotal (I-squared = 18.2%, p = 0.296)		19.60 (2.95, 130.6 3.76 (1.14, 17.39) 2.12 (1.74, 2.59) 5.91 (2.46, 14.19) 7.72 (2.11, 28.18) 8.84 (4.23, 18.48) 3.56 (1.21, 5.90)	00.13 7.41 67.09 12.94 3.08 9.34 100.00	79 (P) 179 (P) 8910 (CS) 462 (R) 108 (R) 4226 (R) 13964
Severe illness vs moderate/mild Bezzio et al., 2020 [28] Colaneri et al., 2020 [33] Guan et al., 2020b [8] Feng et al., 2020 [37] Hu et al., 2020 [42] Ji et al., 2020 [42] Li et al., 2020 [43] Li et al., 2020 [7] Sun et al., 2020a [62] Tian et al., 2020 [66] Wu et al., 2020 [74] Subtotal (I-squared = 24.5%, p = 0.218)		5.87 (1.15, 29.66) 4.06 (1.04, 15.72) 2.55 (1.72, 3.79) 2.17 (1.39, 3.40) 2.96 (1.81, 4.83) 9.75 (4.20, 22.63) 2.24 (1.94, 2.78) 2.170 (3.78, 124, 5 5.16 (2.55, 10.45) 12.75 (6.74, 24.10 2.55 (1.94, 3.17)	0.18 0.69 20.80 21.52 12.48 0.44 41.08 00.01 2.31 )0.50 100.00	79 (P) 44 (R) 1099 (R) 476 (CS) 323 (R) 208 (R) 548 (R) 555 (CS) 262 (R) 280 (R) 3374
Admitted vs not admitted to ICU MMWR., 2020 [25] Du et al., 2020a [10] MMWR., 2020 [89] Subtotal (I-squared = 76.3%, p = 0.015) Age in years ≥60 vs ≤60		1.20 (0.95, 1.51) 0.84 (0.34, 2.03) 2.62 (1.81, 3.78) 1.48 (0.66, 2.30)	42.48 30.33 27.19 100.00	7162 (CS) 109 (R) 4226 (R) 11497
Death VS Survival Deng et al., 2020 [5] Grasselli et al., 2020 [39] Nikpouraghdam et al., 2020 [54] Richardson et al.,2020 [59] Verity et al., 2020 [68] Wang et al., 2020 [70] Subtotal (I-squared = 95.5%, p = 0.000)		9.98 (8.53, 11.69) 3.29 (2.52, 4.30) 3.09 (2.33, 4.09) 4.14 (3.27, 5.24) 9.98 (8.53, 11.69) 18.12 (4.79, 68.57) 6.09 (3.53, 8.66)	19.29 20.30 20.31 20.19 19.29 )0.63 100.00	44672 (CS) 1591 (R) 2968 (R) 5700 (CS) 45695 (CS) 107 (R) 100733
Severe illness vs moderate/mild Pereira et al., 2020 [56] Wang et al., 2020 [72] Zhang et al., 2020 [84] Yu et al., 2020 [80] Subtotal (I-squared = 0.0%, p = 0.714)		3.85 (1.46, 10.18) 6.21 (2.11, 18.23) 11.47 (4.40, 29.88) 3.94 (0.79, 29.53) 4.91 (1.35, 8.47)	66.59 19.48 7.80 6.13 100.00	90 (R) 393 (R) 115 (R) 333 (CS)
-4 Decreased F	IIIIIIIIIII 0 1 2 4 6 8 12 Xisk Increased Risk	CS cross-sectional ICU intensive care ur P prospective R retrospective	nit	

Fig 6.

Author, year, Ref	OR (95% CI)	% sample size Weight (study design)
Death vs survival AI-Rousan, 2020 [27] Deng et al., 2020 [55] Du et al., 2020 [35] Leung et al., 2020 [52] Mehra et al., 2020 [54] Richardson et al., 2020 [54] Richardson et al., 2020 [59] Tang et al., 2020 [70] Wang et al., 2020 [70] Wang et al., 2020 [77] Yang et al., 2020 [77] Yang et al., 2020 [78] Yao et al., 2020 [79] Hu et al., 2020 [79] Subtotal (I-squared = 38.7%, p = 0.058)	$\begin{array}{c} 1.14 & (0.97, 1.35 \\ 1.60 & (1.48, 1.92 \\ 0.74 & (0.29, 1.84 \\ 1.19 & (0.62, 2.26 \\ 1.27 & (1.05, 1.53 \\ 1.04 & (0.57, 1.90 \\ 1.21 & (0.91, 1.62 \\ 1.23 & (1.01, 1.49 \\ 1.57 & (1.03, 2.40 \\ 6.11 & (1.66, 22.44 \\ 1.73 & (1.00, 3.00 \\ 2.93 & (1.62, 5.32 \\ 6.16 & (2.03, 18.6 \\ 1.89 & (1.41, 2.53 \\ 2.33 & (0.68, 7.90 \\ 2.21 & (0.73, 6.70 \\ 1.34 & (1.18, 1.50 \\ \end{array}$	) 17.37 2765 (CS) ) 16.03 44672 (CS) ) 3.60 179 (P) ) 3.27 154 (CS) ) 15.16 8910 (CS) ) 4.63 218 (CS) ) 10.79 2968 (R) ) 15.16 5700 (CS) ) 4.41 449 (CS) 30.02 107 (R) ) 2.30 393 (P) 0.72 193 (R) 50.04 212 (R) ) 6.03 1476 (CS) ) 0.19 108 (R) ) 0.28 105 (R) ) 100.00 68609
Bi et al., 2020 [32] Colaneri et al., 2020 [33] Deng et al., 2020 [34] Feng et al., 2020 [37] Gong et al., 2020 [37] Gong et al., 2020 [38] Guan et al., 2020 [47] Han et al., 2020 [42] Ji et al., 2020 [45] Li et al., 2020 [45] Li et al., 2020 [45] Li et al., 2020 [55] Qin et al., 2020 [55] Qin et al., 2020 [66] To et al., 2020 [66] To et al., 2020 [66] To et al., 2020 [71] Wan et al., 2020 [66] To at al., 2020 [73] Wu et al., 2020 [74] Zhang et al., 2020 [73] Wu et al., 2020 [73] Wu et al., 2020 [74] Zhang et al., 2020 [74] Zhang et al., 2020 [76] Du et al., 2020	$\begin{array}{c} 2.50 & (1.10, 6.10 \\ 0.99 & (0.46, 1.93 \\ 2.60 & (0.67, 10.0 \\ 1.79 & (0.83, 3.84 \\ 1.60 & (1.04, 2.45 \\ 1.64 & (0.73, 3.70 \\ 0.97 & (0.70, 1.36 \\ 0.94 & (0.54, 1.65 \\ 1.13 & (0.73, 1.76 \\ 2.07 & (0.98, 4.34 \\ 1.51 & (1.32, 1.71 \\ 1.50 & (0.57, 3.88 \\ 1.60 & (1.14, 2.24 \\ 1.78 & (1.15, 2.76 \\ 1.27 & (0.86, 1.86 \\ 0.84 & (0.25, 2.78 \\ 2.23 & (0.90, 5.10 \\ 1.48 & (0.24, 6.83 \\ 0.91 & (0.11, 1.91 \\ 1.62 & (0.56, 4.71 \\ 1.62 & (0.56, 3.55 \\ 3.36 & (1.31, 8.61 \\ 3.45 & (1.46, 8.17 \\ 4.60 & (1.70, 12.6 \\ 2.480 & (1.80, 342 \\ 1.85 & (0.77, 4.45 \\ 2.66 & (1.37, 5.17 \\ 1.02 & (0.40, 2.55 \\ 1.26 & (0.56, 2.84 \\ 1.35 & (1.23, 1.47 \\ 0.23 & (0.02, 3.01 \\ 1.51 & (0.23, 0.02 & 3.01 \\ 1.51 & (0.23, 0.02 & 3.01 \\ 1.51 & (0.23, 0.02 & 3.01 \\ 1.51 & (0.23, 0.02 & 3.01 \\ 1.51 & (0.23, 0.02 & 3.01 \\ 1.51 & (0.56, 2.34 \\ 1.51 & (0.23, 1.47 \\ 0.23 & (0.02, 3.01 \\ 1.51 & (0.56, 2.34 \\ 1.51 & (0.23, 0.02 & 3.01 \\ 1.51 & (0.56, 2.34 \\ 1.$	0.24 391 (R) 2.73 145 (R) 60.07 44 (R) 0.65 112 (R) 0.65 112 (R) 13.54 1099 (R) 13.54 1099 (R) 13.54 1099 (R) 0.52 208 (R) 38.78 5771 (CS) 0.54 83 (CS) 14.87 548 (R) 2.28 333 (CS) 14.87 548 (R) 0.33 116 (R) 1.42 262 (R) 0.34 115 (CS) 0.34 93 (CS) 1.82 135 (CS) 0.34 115 (R) 0.14 23 (R) 1.82 252 (R) 0.34 115 (R) 0.13 115 (R) 0.13 115 (R) 0.41 487 (CS) 1.28 90 (R) 1.31 109 (R) 1.000 13426
AggarWal et al. 2020 [26] Kalligeros et al., 2020 [53] Simonnet et al., 2020 [61] Sun et al., 2020 [63] Du et al., 2020 Subtotal (I-squared = 2.9%, p = 0.398)	0.23 (0.02, 3.01 2.40 (0.87, 6.64 2.41 (1.26, 4.62 2.83 (1.02, 7.85 1.00 (0.18, 5.45 1.84 (0.81, 4.17 1.52 (0.69, 2.36	) 29,28 16 (CS) ) 8,18 103 (R) ) 23,45 198 (R) ) 5.87 124 (R) ) 9,78 116 (R) ) 23,45 109 (R) ) 100.00 666
I     I     I     I       -4     0     1     2     4     6       Decreased Risk     Increased Risk	CS cross-sectional ICU intensive care u P prospective R retrospective	unit





